• LAST PRICE
    3.8600
  • TODAY'S CHANGE (%)
    Trending Up0.1900 (5.1771%)
  • Bid / Lots
    3.8000/ 5
  • Ask / Lots
    3.9000/ 4
  • Open / Previous Close
    3.6300 / 3.6700
  • Day Range
    Low 3.6105
    High 3.9000
  • 52 Week Range
    Low 1.0800
    High 6.1400
  • Volume
    736,406
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 3.67
TimeVolumeGTHX
09:32 ET68373.6771
09:38 ET6393.6105
09:39 ET1003.645
09:41 ET31693.665
09:43 ET27843.67
09:45 ET1003.66
09:48 ET5003.68
09:50 ET51373.72
09:52 ET102193.73
09:54 ET7503.75
09:56 ET16003.73
09:57 ET9843.725
09:59 ET9003.71
10:01 ET22703.725
10:03 ET4003.72
10:06 ET4003.73
10:08 ET5083.745
10:10 ET54103.74
10:12 ET12003.73
10:14 ET30003.73
10:15 ET21053.721
10:17 ET9583.73
10:19 ET162053.73
10:21 ET68093.74
10:24 ET116183.77
10:26 ET193533.74
10:28 ET82633.78
10:30 ET269933.74
10:32 ET12953.75
10:33 ET80003.75
10:35 ET10393.73
10:37 ET4003.745
10:39 ET45163.76
10:42 ET8503.76
10:44 ET11003.7601
10:46 ET4003.76
10:48 ET22003.755
10:50 ET2003.76
10:51 ET78413.79
10:53 ET33653.82
10:55 ET60613.78
10:57 ET53303.79
11:02 ET10003.79
11:04 ET20003.795
11:06 ET1003.8
11:08 ET58543.8
11:09 ET235353.795
11:13 ET30003.8
11:15 ET59403.8399
11:18 ET13613.815
11:20 ET19573.81
11:24 ET145423.82
11:26 ET19203.83
11:27 ET5003.8201
11:29 ET84143.8
11:31 ET15833.81
11:33 ET4263.8
11:36 ET1003.8001
11:40 ET4003.805
11:42 ET3003.7901
11:44 ET14053.805
11:45 ET5003.805
11:47 ET18003.815
11:49 ET10003.81
11:51 ET8003.8
11:56 ET7603.81
11:58 ET2003.815
12:02 ET192683.8
12:03 ET53003.805
12:09 ET4283.805
12:12 ET1003.805
12:14 ET4063.8
12:16 ET10763.815
12:18 ET5573.82
12:20 ET58933.77
12:21 ET23763.77
12:23 ET5003.75
12:25 ET1233.75
12:27 ET19593.7399
12:30 ET15003.7399
12:32 ET2063.735
12:34 ET5003.735
12:36 ET9983.73
12:39 ET18483.73
12:43 ET2033.735
12:48 ET3223.732
12:50 ET1003.735
12:54 ET1003.735
12:57 ET10103.73
12:59 ET61143.705
01:01 ET8303.71
01:03 ET11163.72
01:08 ET9003.715
01:10 ET4503.72
01:14 ET14453.72
01:15 ET38743.72
01:21 ET18343.71
01:24 ET17023.71
01:26 ET27973.7
01:28 ET66313.705
01:30 ET4243.71
01:32 ET6033.7
01:33 ET3063.705
01:35 ET2063.705
01:37 ET17003.7001
01:42 ET29833.71
01:44 ET1003.71
01:46 ET2003.7179
01:48 ET11003.725
01:50 ET11063.73
01:51 ET2003.74
01:57 ET72003.735
02:00 ET4003.73
02:09 ET1283.73
02:11 ET3003.74
02:13 ET1003.74
02:18 ET20763.73
02:20 ET1003.735
02:26 ET3093.735
02:27 ET29063.735
02:29 ET7003.74
02:33 ET20003.745
02:38 ET2503.7412
02:44 ET22003.75
02:45 ET70863.755
02:47 ET23063.75
02:51 ET2003.745
03:00 ET2003.745
03:03 ET3003.745
03:05 ET1003.745
03:07 ET10003.745
03:12 ET5063.745
03:14 ET1003.74
03:16 ET5003.74
03:18 ET40923.745
03:20 ET1003.745
03:21 ET13353.755
03:23 ET15363.76
03:25 ET30653.76
03:27 ET375053.815
03:30 ET10003.8101
03:32 ET58173.82
03:34 ET26033.835
03:36 ET46283.82
03:38 ET10003.8231
03:39 ET19033.825
03:41 ET5003.83
03:43 ET196553.83
03:45 ET13413.82
03:48 ET27103.8
03:50 ET150703.845
03:52 ET487643.8901
03:54 ET285043.855
03:56 ET472143.895
03:57 ET29503.89
03:59 ET518733.86
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGTHX
G1 Therapeutics Inc
184.0M
-6.3x
---
United StatesCDXC
Chromadex Corp
219.8M
-65.3x
---
United StatesALIM
Alimera Sciences Inc
291.3M
-3.6x
---
United StatesPSNL
Personalis Inc
116.9M
-1.5x
---
United StatesNKTR
Nektar Therapeutics
266.3M
-1.6x
---
United StatesCDXS
Codexis Inc
242.7M
-3.9x
---
As of 2024-07-23

Company Information

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead commercial product, COSELA (trilaciclib), is a therapy indicated to proactively help protect bone marrow (myeloprotection) from the damage of chemotherapy. Its product portfolio consists of Trilaciclib and Lerociclib, both of which are CDK4/6 inhibitors, and a Cyclin-dependent kinase 2 (CDK2) inhibitor. Trilaciclib is a novel therapy designed to transiently arrest cells that are dependent on CDK4/6 for proliferation, including hematopoietic stem and progenitor cells (HSPCs), in the G1 phase. Lerociclib is a differentiated clinical-stage oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. COSELA is a short-acting intravenous CDK4/6 inhibitor. Its CDK2 is an internally discovered inhibitor.

Contact Information

Headquarters
700 Park Offices Drive, Suite 200RESEARCH TRIANGLE PARK, NC, United States 27709
Phone
919-213-9835
Fax
919-741-5830

Executives

Independent Chairman of the Board
Garry Nicholson
President, Chief Executive Officer, Director
John Bailey
Chief Financial Officer
John Umstead V
Chief Operating Officer
Terry Murdock
Chief Legal and People Officer
Monica Thomas

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$191.9M
Revenue (TTM)
$84.0M
Shares Outstanding
52.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.56
EPS
$-0.61
Book Value
$0.68
P/E Ratio
-6.3x
Price/Sales (TTM)
2.3
Price/Cash Flow (TTM)
---
Operating Margin
-27.16%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.